II
IONS icon

IFM Investors’s Ionis Pharmaceuticals IONS Stock Holding History

IFM Investors’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-15,830
Closed -$712K – 607
2021
Q1 		$712K Buy
15,830
+3,181
+25% +$177K 0.02% 582
2020
Q4 		$715K Sell
12,649
-118
-0.9% -$5.88K 0.02% 559
2020
Q3 		$606K Buy
12,767
+3,137
+33% +$174K 0.03% 519
2020
Q2 		$568K Sell
9,630
-2,062
-18% -$115K 0.03% 496
2020
Q1 		$564K Sell
11,692
-333
-3% -$18.6K 0.03% 506
2019
Q4 		$726K Sell
12,025
-209
-2% -$12.5K 0.03% 545
2019
Q3 		$733K Buy
12,234
+3,854
+46% +$251K 0.03% 536
2019
Q2 		$539K Buy
+8,380
New +$592K 0.03% 517

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

IFM Investors's IONS Position: Q2 2021 in Review

IFM Investors sold out of Ionis Pharmaceuticals (IONS) in Q2 2021, closing a stake of 15,830 shares — an estimated $712K sold.

IFM Investors first reported a position in IONS in Q2 2019 and held it in 8 quarters. The position peaked at $733K in Q3 2019. 337 funds tracked by Wall St. Rank hold IONS as of Q2 2021.

  • IFM Investors reported no remaining Ionis Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • IFM Investors sold 15,830 Ionis Pharmaceuticals shares in Q2 2021, an estimated $712K.
  • IFM Investors first reported a position in Ionis Pharmaceuticals in Q2 2019 and held it in 8 quarters.
  • IFM Investors's Ionis Pharmaceuticals position peaked at $733K in Q3 2019.
  • 337 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2021.

Based on IFM Investors's 13F filing for Q2 2021, filed 16 Jul 2021.